The Charnley prosthesis had by far the best and most comprehensive evidence base with better than 90 % implant survival after about 10 years .
Some uncemented stems have shown promising medium-term outcome , but no combination of uncemented cup and stem fulfilled the benchmark criterion of > or = 90 % implant survival at 10 years , which we propose as a minimum requirement for unrestricted clinical use for prostheses used in primary THR .
We have conducted a systematic review of the scientific literature concerning outcome and clinical effectiveness of  prostheses used for primary total hip replacement ( THR ) in Norway .
Life Expectancy and Cost Utility After Total Hip Replacement
In a prospect i ve study of 410 cemented hip replacements in 372 patients with a mean age of 71 years , mortality after 8 years was 33 % .  Mortality for patients with osteoarthrosis  was lower than in an age matched control population , probably because of a preoperative selection of patients . An estimate of costs and adjusted quality of life has shown that total hip replacement has a good cost utility even in the elderly patient . The conclusion of this study is that the indications for hip replacement in the elderly patient can be exp and ed . Such patients should undergo surgery earlier in the course of their disease
The Charnley prosthesis had by far the best and most comprehensive evidence base with better than 90 % implant survival after about 10 years .
Some uncemented stems have shown promising medium-term outcome , but no combination of uncemented cup and stem fulfilled the benchmark criterion of > or = 90 % implant survival at 10 years , which we propose as a minimum requirement for unrestricted clinical use for prostheses used in primary THR .
We have conducted a systematic review of the scientific literature concerning outcome and clinical effectiveness of  prostheses used for primary total hip replacement ( THR ) in Norway .